Back to Journals » Journal of Hepatocellular Carcinoma » Volume 6

Combined hepatocellular cholangiocarcinoma (cHCC-CC): an update of genetics, molecular biology, and therapeutic interventions

Authors Stavraka C, Rush H, Ross P

Received 4 September 2018

Accepted for publication 8 November 2018

Published 28 December 2018 Volume 2019:6 Pages 11—21


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Dr Ahmed Kaseb

Chara Stavraka,1,* Hannah Rush,1,* Paul Ross1,2

1Department of Medical Oncology, Guy’s Cancer, Guy’s & St Thomas’ NHS Foundation Trust, London, UK; 2Department of Oncology, King’s College Hospital NHS Foundation Trust, London, UK

*These authors contributed equally to this work

Abstract: Combined hepatocellular cholangiocarcinoma (CC) is a rare and aggressive primary hepatic malignancy with significant histological and biological heterogeneity. It presents with more aggressive behavior and worse survival outcomes than either hepatocellular carcinoma or CC and remains a diagnostic challenge. An accurate diagnosis is crucial for its optimal management. Major hepatectomy with hilar node resection remains the mainstay of treatment in operable cases. Advances in the genetic and molecular characterization of this tumor will contribute to the better understanding of its pathogenesis and shape its future management.

Keywords: cholangiocarcinoma, hepatocellular carcinoma, combined, genetics, molecular biology, treatment, mixed liver tumors, primary liver cancer

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]